Boston Scientific accounts are for healthcare professionals only.
“NVB-sparing SBRT with hydrogel spacer placement has the potential to significantly reduce the high dose delivered to the NVB. The spacer contributes to this effect by inducing a small but dosimetrically meaningful NVB displacement in the posterior direction. We believe that the described approach to offer clinically meaningful reductions in RiED warrants prospective clinical trials.”
Reference
- Hwang ME, Mayeda M, Shaish H, Elliston CD, Spina CS, Wenske S, et al. Dosimetric feasibility of neurovascular bundle-sparing stereotactic body radiotherapy with periprostatic hydrogel spacer for localized prostate cancer to preserve erectile function. Br J Radiol 2021; 94: 20200433.
SBRT was not the method used in the SpaceOAR Hydrogel single-blind Phase III trial performed to evaluate dosimetric and clinical effects of SpaceOAR Hydrogel. IG-IMRT delivered at 79.2 Gy in 1.8-Gy fractions was the method used.
Results from case studies are not necessarily predictive of results in other cases. Results in other cases may vary.
The content of this article/publication is under the sole responsibility of its author/publisher and does not represent the opinion of BSC.
Caution: U.S. Federal law restricts this device to sale by or on the order of a physician.
CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at www.IFU-BSCI.com. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France.
All images are the property of Boston Scientific. All trademarks are the property of their respective owners.